Clinical trials: Myeloid
Hematologic Malignancies
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
- Trial name
- NCT03320642
- Testing
- Itacitinib, Calcineurin inhibitor
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
Leukemia, Lymphoma
Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00004145
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
This is a single arm open label phase 2 study evaluating the potential effect of ixazomib on the prevention of recurrent or late acute graft-versus-host disease (GVHD) and chronic GVHD at 1-year following reduced intensity (RI)…
- Trial name
- NCT03082677
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Multi-center phase II study of standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of "low-dose" venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days…
- Trial name
- LD-VenEx (NCT05431257)
- Testing
- Venetoclax
- Where
- Denmark
- Volunteers
- 117 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Relapsed Acute Myelogenous Leukemia
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs.
- Trial name
- NCT00939653
- Testing
- Clofarabine, Etoposide, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Leukemia
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy, such as cladribine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258271
- Testing
- filgrastim, cladribine, cytarabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Rochester
Childhood Cancer, ALL, Childhood
Retun-to-school Adaptation Program for Children With Cancer
The aim of this action research is to: Stage 1: Conduct an in-depth investigation into the adaptation challenges faced by children aged 8-17 who are being treated for cancer during their return to school, from both the children's…
- Conditions
- Childhood Cancer, ALL, Childhood, AML, Childhood, Lymphoma
- Trial name
- web-based (NCT06389357)
- Testing
- training and counselling, Interview
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Gazi University
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia.
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT05038592
- Testing
- Decitabine, Tagraxofusp-erzs
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells
AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality.
- Trial name
- CAR-LAM (NCT04169022)
- Testing
- Sample collection
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Drugs used in chemotherapy, such as cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may help cytarabine kill more cancer cells by making them more sensitive to the drug.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00077181
- Testing
- cytarabine, triapine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia
Brentuximab Vedotin + Re-induction Chemotherapy for AML
This research study is a Phase I clinical trial. Phase I trials test the safety of an investigational drug or combination of drugs.
- Trial name
- NCT01830777
- Testing
- Brentuximab Vedotin, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia
Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy
Neutropenia after induction or consolidation therapy for acute myeloid leukemia (AML) patients is associated with a high morbi-mortality rates, especially due to infectious complications.
- Trial name
- DECLAM (NCT03450512)
- Testing
- prospective study on digestive affections in an homogeneous cohort of hematological patients
- Where
- 3 sites in France
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Acute Myeloid Leukemia, Pediatric
Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia
The investigators adopted the CAMS（Chinese Academy of Medical Sciences）-2009 trial for pediatric acute myeloid leukemia (AML) patients between 2009 to 2015, in which a risk-stratified strategy and dose-dense intensive…
- Trial name
- NCT03165851
- Testing
- Risk-stratified therapy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
AML, Refractory
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options.
- Conditions
- AML, Refractory, Relapsed
- Trial name
- NCT06265545
- Testing
- Ivosidenib, Venetoclax, Gilteritinib
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
This randomized phase II trial studies how well choline magnesium trisalicylate with idarubicin and cytarabine works in treating patients with acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT02144675
- Testing
- choline magnesium trisalicylate, idarubicin, cytarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Rutgers, The State University of New Jersey
Leukemia, Myeloid
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
- Conditions
- Leukemia, Myeloid, Acute, Newly Diagnosed
- Trial name
- NCT05673057
- Testing
- MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax
- Where
- 9 sites in France, Lithuania and 2 more
- Volunteers
- 80 people
- Sponsor
- Molecular Partners AG
Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia and Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap…
- Conditions
- Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified, Recurrent Atypical Chronic Myeloid Leukemia
- Trial name
- NCT05549661
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Study of TCP-ATRA for Adult Patients With AML and MDS
Acute Myeloid Leukemia (AML) is a diverse disease that is fatal in the majority of patients. Acute promyelocytic leukemia (APL) however, a subtype of AML accounting for 5% of all cases, is very curable.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Leukemia
- Trial name
- TCP-ATRA (NCT02273102)
- Testing
- Tranylcypromine, Tretinoin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Miami
AML, Acute Myelogenous Leukemia
Diagnosis and Treatment of Periodontal Disease in Patients With AML
This is a phase 2 randomized controlled trial of pre-chemotherapy periodontal deep cleaning in Acute Myelogenous Leukemia (AML) patients with asymptomatic periodontitis.
- Trial name
- NCT04530695
- Testing
- Scaling and Root Planing
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Myelogenous Leukemia in Chronic Phase
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
"This is a single-arm, open-label, multi-center study of complete molecular response (CMR) in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).
- Trial name
- MACS1428 (NCT01227577)
- Testing
- Nilotinib
- Where
- 32 sites in United States
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.